HLA-C^* 04:01 is a Genetic Risk Allele for Severe Course of COVID-19

Competing Interest Statement

This study was partially funded by Roche Sequencing Solutions, Inc., which also provided material for exome sequencing. Bettina Heidecker, MD is an inventor on patents that use RNA for diagnosis of myocarditis. Juerg H. Beer, MD has received grant support from the Swiss National Science Foundation and of the Swiss Heart Foundation. Martin Witzenrath, MD is supported by grants from the German Research Foundation, SFB-TR84 C6 and C9, SFB 1449 B2, by the German Ministry of Education and Research (BMBF) in the framework of the CAPSyS (01ZX1304B), CAPSyS-COVID (01ZX1604B), SYMPATH (01ZX1906A), PROVID (01KI20160A) P4C (16GW0141), MAPVAP (16GW0247), NUM-NAPKON (01KX2021), and by the Berlin Institute of Health (CM-COVID). Martin Witzenrath, MD received research funding from the Deutsche Forschungsgemeinschaft, Bundesministerium fuer Bildung und Forschung, Deutsche Gesellschaft fuer Pneumologie, European Respiratory Society, Marie Curie Foundation, Else Kroener Fresenius Stiftung, Capnetz Stiftung, International Max Planck Research School, Actelion, Bayer Health Care, Biotest, Boehringer Ingelheim, Noxxon, Pantherna, Quark Pharma, Silence Therapeutics, Takeda Pharma, Vaxxilon, sowie fuer Vortraege oder Beratertaetigkeit von Actelion, Aptarion, Astra Zeneca, Bayer Health Care, Berlin Chemie, Biotest, Boehringer Ingelheim, Chiesi, Glaxo Smith Kline, Novartis, Noxxon, Pantherna, Silence Therapeutics, Sinoxa, Teva und Vaxxilon.

Clinical Trial

German and WHO international clinical trials registry, DRKS00021688

Funding Statement

This work was supported through research funding from Roche Sequencing Solutions, Inc. and a project grant from the Swiss National Science Foundation issued to Bettina Heidecker, MD (Money Follows Researcher Program). This work was supported by the Berlin Institutes of Health (B.I.H. support to the PA-COVID-19 study group, represented by L.E.S and M.W.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the ethics committee of Charite Universitaetsmedizin Berlin, Germany (EA2/066/20), the Ethikkommission Nordwest- und Zentralschweiz, Basel, Switzerland (2020-00952), and the Ethics Committee of the Hospital Universitario de Valme, Sevilla Spain (1346-N-16).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes